From IND to NDA Approval: Timelines, Complete Response Letters and Cost
From IND to NDA approval
How long it takes, why applications get a complete response letter, who does the work, and roughly what it costs. Built from public FDA records and published research.
The whole path, from the first IND to the first year after approval
Each phase with typical duration, what happens and what it costs, and why most programs never reach an NDA.
The milestones inside the PDUFA clock, and how approvals split between priority and standard review.
Why FDA issued 294 letters on original applications, and how long each kind took to recover from.
What goes into each CTD module, and the fifteen-plus functions that produce it.
Direct cost ranges by phase, including the share spent on writing and publishing the dossiers.
What an IND files over its life, and where IND time and money go.
Seven levers ordered by the months at stake, and eight questions to check your own program.
Manufacturing, not clinical data, is the most common reason for a complete response letter
Share of 294 complete response letters on original applications citing each category. The full breakdown, and how long each kind of letter took to recover from, is in the report.
Four things worth knowing
The first cycle usually works
CDER approved 84% of novel drugs on the first cycle in 2023, 74% in 2024 and about 85% in 2025. The review clock is predictable. Whether the first cycle ends in approval is what varies.
A second cycle costs about 18 months
In the published letters, the median from a first complete response letter to approval was about 18 months. Only about a quarter of applications were approved within 12 months.
Manufacturing letters are the most preventable
Half of the letters cite only manufacturing, facility or microbiology problems. Even those took a median of almost 15 months to resolve, longer than a standard review.
IND overhead is mostly sequence overhead
Every sequence carries a cover letter, Form 1571, QC, publishing and validation. FDA asks for information amendments no more often than about every 30 days, and batching them is the cheapest saving available.
From IND to NDA approval
For regulatory affairs, regulatory operations, clinical, CMC and program leads, and for anyone budgeting a development program.
- Key findings
- The path and the timeline, with costs by phase
- The FDA review and its milestones
- Why applications get a complete response letter
- What a second cycle costs in time
- What goes into the NDA, and who writes it
- The IND, and where its time and money go
- Seven levers and an eight-question self-check
Frequently asked
Where does the data come from?
Only public sources: the FDA Drugs@FDA data files, the complete response letters FDA publishes on openFDA, CDER's annual approval reports, and published research. No customer data is used.
How were the complete response letters classified?
By fixed rules, using each letter's own section headings (for example PRODUCT QUALITY and FACILITY INSPECTIONS) and set phrases. No AI was used to classify them.
Are the cost figures a quote?
No. They are directional ranges from published sources, useful for planning and for testing a budget.
Can you assess our own program against this?
Yes. We run IND and NDA readiness reviews that compare your timeline and dossier with the path in this report and rank what to fix first.
Planning an IND or an NDA?
We run readiness reviews for IND and NDA programs: where your timeline and dossier stand against the path in this report, and what to fix first.
